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Abstract
In islet transplantation, nonimmunological factors such as lim-
ited growth capacity or increased death rate could reduce the
beta cell mass in the graft and lead to failure of the transplant.
We studied the evolution of beta cell replication and mass after
transplantation of insufficient, minimally sufficient, or exces-
sive islet tissue. Streptozocin diabetic C57BL/6 mice received
150 or 300 syngeneic islets under the kidney capsule and nor-
mal mice received 300 islets. In streptozocin diabetic mice 300
islets restored normoglycemia; beta cell replication in trans-
planted islets was similar to replication in normal pancreas and
beta cell mass in the graft remained constant. In contrast, 150
islets were insufficient to achieve normoglycemia; beta cell rep-
lication was increased initially but not by 18 or 30 d despite
persistent hyperglycemia, and beta cell mass fell progressively.
When islets were transplanted into normal recipients, beta cell
replication remained normal but beta cells underwent atrophy
and mass in the graft was substantially reduced. Therefore,
with a successful islet transplant, in diabetic mice beta cell
replication and mass remain constant. In contrast, when insuffi-
cient islet tissue is transplanted an initial increase in beta cell
replication can not compensate for a decline in beta cell mass.
When excessive islet tissue is transplanted, beta cell mass is
reduced despite normal beta cell replication. (J. Clin. Invest.
1993. 91:780-787.) Key words: diabetes * endocrine pancreas*
insulin * islet of Langerhans * beta cell replication
Introduction
Transplantation of islet cells was able to restore blood glucose
in diabetic rats almost 20 years ago ( 1, 2). However, in diabetic
patients the first successful islet transplants were achieved only
very recently (3-5). Large numbers of islets must be trans-
planted into these patients to normalize the blood glucose, well
in excess of the 10-30% of the total beta cell mass that is suffi-
cient to maintain normoglycemia after partial pancreatecto-
mies (6-8). The reasons for the need ofsuch a large amount of
islet tissue are not well known. The early and late failures of
islet autotransplants in animal models suggest that the immu-
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nological factors alone can not explain the poor results (9).
Loss of islets during the transplantation, lack of engraftment,
anoxia, and islet death in the first days could, among other
causes, decrease the effective beta cell mass and contribute to
the early failure of the graft. A toxic effect of immunosuppres-
sive treatment on beta cell function can also be invoked ( 10,
11 ). The mass oftransplanted islets seems to play a critical role
in the outcome of the graft. A critical amount of islet tissue
must be transplanted to achieve normoglycemia and late fail-
ures have been shown to depend on the number of initially
transplanted islets ( 12-14). Either a limitation in the growth
capacity oftransplanted islets compared to endogenous pancre-
atic islets, or an increased death rate overwhelming the growth
capacity could lead to continuous loss of beta cell mass and
failure ofthe graft. Such factors could help explain the discrep-
ancies between the long-term success of whole pancreas trans-
plantation and the limited survival of islet transplantations in
large animals and in humans (3, 10, 15). However, little is
known about the growth capacity and fate oftransplanted beta
cells and the factors that modify such events. Thus, we studied
the evolution of beta cell replication and mass after transplan-
tation of differing quantities of islet tissue that were insuffi-
cient, minimally sufficient, or excessive, three different situa-
tions that might be found in clinical transplantation.
Methods
Animals
Male inbred C57BL/6 mice, aged 10 to 14 wk, were used as donors and
recipients ofthe transplantation. The recipients were made diabetic by
a single intraperitoneal injection of streptozocin (Streptozotocin,
Sigma Immunochemicals, St. Louis, MO) 200 mg/kg body wt, freshly
dissolved in citrate buffer (pH = 4.5). Before transplantation, diabetes
was confirmed by the presence of hyperglycemia, weight loss, and poly-
uria. Only those mice with a blood glucose higher than 20 mmol/liter
were transplanted. On days 2, 4, 6, 10, 18, and 30 after transplantation
blood glucose was determined between 9 and 11 a.m. Blood was ob-
tained from the snipped tail with a heparinized microcapillary tube and
glucose was measured with a portable glucose meter (Accu-Check II;
Boehringer-Mannheim Biochemicals, Indianapolis, IN). Body weight
was measured on the same days. The animals were kept under conven-
tional conditions in climatized rooms with free access to tap water and
standard pelleted food.
Animal groups
Eight groups of transplanted animals (Table I) were studied: (a) strep-
tozocin diabetic mice transplanted with 300 islets that had the grafts
removed after 10 d (group 1, n = 6), 18 d (group 2, n = 4), or 30 d
(group 3, n = 5); (b) streptozocin diabetic mice transplanted with 150
islets that had the grafts removed after 10 d (group 4, n = 6), 18 d
(group 5, n = 6), or 30 d (group 6, n = 6); (c) normoglycemic mice
(previously injected with citrate buffer alone) transplanted with 300
islets that had both the grafts and the endogenous pancreases removed
after I0 (group 7, n = I 1) or 30 d (group 8, n = 11). In these two last
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groups six animals were studied for beta cell replication and beta cell
mass, and the remaining five for insulin content. The rationale for the
number of islets transplanted was that 300 islets is the minimum
amount that can always restore normoglycemia in diabetic C57B 1/6
mice, while a transplant of 150 islets does not achieve normoglycemia
( 16, 17). Therefore, we had a model of successful transplantation with
a minimum amount of beta cell mass and a model of unsuccessful
transplantation due to an insufficient beta cell mass. In addition an
excessive beta cell mass was obtained by transplantation in the normal
recipients.
Three control groups of nontransplanted animals were studied. A
group ofstreptozocin diabetic mice (n = 9) had their blood glucose and
body weight checked at the same time points as the transplanted mice.
Two groups of normal mice of similar body weight as group 7 (n = 11 )
and as group 8 (n = 11 ) were killed to determine the pancreatic beta
cell mass (n = 6) and insulin content (n = 5). Finally the beta cell mass
of 300 (n = 9) and 150 isolated islets (n = 7), as well as the insulin
content of 300 isolated islets (n = 5), were determined.
Islet isolation and transplantation
Under anesthesia with sodium amobarbital (Amytal® sodium; Eli Lilly
& Co., Indianapolis, IN) 200 mg/kg intraperitoneally, a laparotomy
was performed and the pancreas was exposed. The common bile duct
was ligated at the ampulla of Vater, cannulated proximally with a 27
gauge needle, and injected with 2 ml of a solution containing 2 mg of
collagenase (collagenase from Clostridium histoliticum; Serva, Heidel-
berg, Germany) per ml of M-199 medium (GIBCO BRL, Gaithers-
burg, MD) with 26 mM NaHCO3. The animal was killed and the
pancreas dissected from surrounding tissues, removed, and incubated
in a stationary bath for 22-26 min at 370C. After incubation the di-
gested tissue was washed three times with M-l 99 media with 26 mM
NaHCO3 and 10% heat inactivated newborn calf serum (GIBCO
BRL), and filtered through a collector tissue sieve (40 mesh; Fisher
Scientific, Pittsburgh, PA). The islets were separated by a density gra-
dient (Histopaque-1077; Sigma Immunochemicals) centrifuged at
2,500 rpm for 20 min (18). Isolated islets were recovered from the
gradient interface, washed three times with the same media, placed in a
60 X 15-mm plastic petri dish (Fisher Scientific), and hand-picked
under a stereomicroscope two or three times until a population ofpure
islets was obtained. Islets > 75 and < 250 ,um in diameter were col-
lected and carefully counted into groups of 300 and 150 islets. Islets
with ragged edges suggesting overdigestion were not used. With these
restrictions the final yield was 120-150 islets per pancreas.
The islets were transplanted under the kidney capsule of the recipi-
ents on the same day ofthe isolation. The islets were centrifugated in a
200-,l pipette tip (USA Scientific Plastics, Ocala, FL) previously
plugged with Gelfoam® (The Upjohn Co., Kalamazoo, MI). With the
mouse under light ether anesthesia, the left kidney was exposed
through a lumbar incision. A capsulotomy was performed in the lower
kidney pole and the islets injected under the kidney capsule of the
upper pole through the pipette tip. The capsulotomy was left unsu-
tured.
Graft and pancreas removal
On the day of graft removal the mice were injected with 5-bromo-
2'deoxyuridine (BrdU)' (Sigma Immunochemicals), 100mg/kg body
wt intraperitoneally, and 6 h later the graft was removed. With the
mouse under light ether anesthesia the left kidney was exposed and the
graft identified as a white patch. The kidney capsule surrounding the
graft was incised and removed with the graft. Usually all the graft was
removed with the capsule; in the few cases where the grafted islets were
infiltrating the kidney cortex a second piece of tissue was also taken to
ensure that the entire graft was taken. A left nephrectomy was subse-
quently performed in groups 1-6 and the blood glucose level and body
weight determined on the following days. All normoglycemic mice
(groups 1-3) returned to hyperglycemia after graft excision and in al-
1. Abbreviation used in this paper: BrdU, 5-bromo-2'deoxyuridine.
ready hyperglycemic mice (groups 4-6) blood glucose values increased
and body weight decreased. In groups 7 and 8 the animals were killed
after the graft recovery and the pancreas was excised, blotted, weighed,
and fixed in Bouin's solution. Subsequently, the pancreas was embed-
ded in paraffin.
Immunocytochemistry
After removal, the graft was immediately immersed in a preweighed
drop of Bouin's fixative. The weight of the graft was determined by
reweighing on a balance reading to 0.05 mg (type H 16; Mettler Instru-
ments Corp., NJ). The graft was processed for plastic embedding (Ar-
aldite, Ernest F. Fullan, Inc., Latham, NY). 1 gm sections were affixed
to glass by heat; the plastic resin was removed with sodium metoxide.
To assess the beta cell replication the sections were double stained for
BrdU and for the endocrine non-beta cells of the islets with immuno-
peroxidase. BrdU is a thymidine analogue that is incorporated into
newly synthesized DNA of cells in the S phase of the cell cycle ( 19).
Immunostaining for BrdU used a Cell Proliferation Kit (Amersham
International, Amersham, UK). The sections were incubated with a
mouse monoclonal antibody anti-BrdU in a solution containing nu-
clease for DNA denaturation for 48 h at 40C, washed with PBS (pH
= 7.4), incubated with an affinity-purified peroxidase anti-mouse Ig,
and stained with 3,3'-diaminobenzidine tetrahydrochloride plus a sub-
strate/intensifier containing hydrogen peroxide and nickel chloride/
cobalt chloride. The sections were then washed with 0.01 mM HCI and
with tap water, soaked in PBS plus 1% lamb serum (GIBCO BRL), and
subsequently stained for the endocrine non-beta cells. The primary
antibody was a cocktail of antibodies: rabbit anti-bovine glucagon
(final dilution 1:3,000, gift of Dr. M. Appel, Cytotheraputics, Inc.,
Providence, RI), rabbit anti-synthetic somatostatin, final dilution
1:300, made in our own laboratory), and rabbit anti-bovine pancreatic
polypeptide, 1:3,000 final dilution, gift of Dr. R. Chance, Eli Lilly &
Co.). The sections were incubated with this cocktail for 48 h at 4VC,
washed with PBS, incubated with a goat anti-rabbit IgG as secondary
antibody, washed with Tris-chloride (pH = 7.4), incubated with a per-
oxidase anti-rabbit serum (Cappel Laboratories, Cochranville, PA)
and stained with 3,3'-diaminobenzidine tetrahydrochloride (Sigma Im-
munochemicals) and hydrogen peroxide (Fisher Scientific).
Beta cell replication
On the stained sections the islet tissue was easily identified on the light
microscope level (Fig. 1 ): the endocrine non-beta cells with an orange-
brown cytosol, and the beta cells with a nonstained cytosol. BrdU posi-
tive staining was seen as blue/black nuclei. Using an Olympus BH-2
microscope connected to a video camera with a black and white moni-
tor at a final magnification of 760, beta cells and BrdU-positive beta
cells were counted; results were expressed as the percentage of BrdU-
positive beta cells. We stained the endocrine non-beta cells instead of
the beta cells because cells with stained cytosol and nucleus are difficult
to discern and also because chronic hyperglycemia, which is associated
with beta cell degranulation resulting in a weak or negative staining of
beta cells, was expected in groups 4-6. At least 1,200 cells were counted
per graft; all the endocrine cells in a section were counted, and when
needed, a second section was included. A similar procedure was used to
stain the paraffin-embedded pancreatic sections. The sections were sys-
tematically sampled, counting cells until a minimum of 1,200 endo-
crine cells per pancreas was scored for BrdU.
Beta cell mass
Beta cell mass was measured by point counting morphometry on im-
munoperoxidase-stained sections of graft and endogenous pancreas.
For the graft tissue each section was covered systematically at a magni-
fication of 760 using a 48-point grid to obtain the number of intercepts
over beta cells, over endocrine non-beta cells, and over other tissue.
The beta cell relative volume was calculated by dividing the intercepts
over beta cells by intercepts over total tissue; then the beta cell mass was
estimated by multiplying beta cell relative volume by graft weight. A
nomogram relating number of points counted to volume density and
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Figure 1. Micrograph showing transplanted islet tissue. (A) At low
magnification the well preserved islet tissue is easily distinguished
under the kidney capsule (c). Semi-thin (1 jrm) section stained with
methylene blue. Magnification bar = 25 jm. (B) At higher magnifi-
cation showing double immunostained islet tissue transplanted under
kidney capsule (c). Cytoplasmic staining for noninsulin islet hor-
mones identifies endocrine non-beta cells (arrow). Replicating beta
cell (curved arrow) is identified by BrdU-positive nucleus, endocrine
cell morphology and lack of cytoplasmic staining. Color differences
(blue-black BrdU-positive nucleus, orange-brown islet hormone-pos-
itive cytoplasm) enhanced the visual recognition of the labeled cells
on the sections. Immunoperoxidase stained 1 jim section, hematoxy-
lin counterstained. Magnification bar = 100 jm.
expected relative standard error in percentage of mean (< 10%) had
been used to determine the number ofintercepts needed for a represen-
tative sampling (20). The beta cell mass of the pancreas was assessed
similarly.
To determine the beta cell mass of the islets at the time of the
transplantation, eight groups of 300 islets and nine groups of 150 islets
isolated on five different days were washed in PBS after isolation and
pelleted in Bouin's fixative. Any excess of Bouin's was removed by
capillary action and the pellet was immersed in a preweighed drop of
Bouin's that was reweighed to obtain the weight of the islet pellet. Beta
cell mass was obtained by multiplying the weight of the islets by the
percentage of beta cell volume as derived from our data (91.6%). To
determine the accuracy of these measurements, 50 islets from each of
three different isolations were measured for individual islet diameter
and volume. To do this, islets were photographed on an inverted phase
microscope. Islet perimeter was measured on the photographs using an
electronic planimetry program (Sigma Scan; Jandel Scientific, Corte
Madera, CA). For calculations islets were assumed to be spheres, and
the individual and mean islet diameters and volumes were calculated.
Beta cell area
The mean cross-sectional area of individual beta cells, a measure of
beta cell size, was determined on immunoperoxidase-stained sections
of grafts and isolated islets. The area of beta cells from all grafts was
measured on the same sections on which beta cell mass and replication
were determined. The area of beta cells on the day of transplantation
was determined on sections from the same pellets of 150 and 300 iso-
lated islets used to measure the initially transplanted beta cell mass.
The pellets had been embedded in plastic (Araldite) and 1-,jm sections
stained by immunoperoxidase as described before for the graft samples.
10 pellets from three different isolations were used. For both grafts and
isolated islets the beta cell nuclei on a random field were counted (70-
130 nuclei). The perimeter of the beta cell tissue in that field was
carefully traced, to exclude any other tissue, on an acetate sheet over-
laid on the monitor, and the beta cell area was then measured with an
electronic planimetry program (Sigma Scan; Jandel Scientific). The
beta cell area was divided by the number of beta cell nuclei in the field
to calculate the area of the individual beta cells. The actual number of
beta cells in the field was in fact higher than the number counted, since
not all beta cells were sectioned across their nuclei and, therefore, the
size of the beta cells was overestimated.
Insulin content
The grafts were removed from the kidney as described above, then
minced and sonicated in acid ethanol. The pancreases were removed,
blotted, weighed, and then stored in acid ethanol at -20'C. Later they
were homogenized using an Ultra Turrax SDT (Tekmar Co., Cincin-
nati, OH). Five groups of 300 islets were sonicated in acid ethanol after
isolation. After sonication or homogenization the samples were ex-
tracted overnight at 4VC. On the following day they were centrifuged at
2,400 rpm for 10 min and the supernatant was stored at -20'C. The
pellet was again sonicated or homogenized in acid ethanol and insulin
extracted overnight. After centrifugation this second supernatant was
added to the first extraction sample. Insulin was measured by radioim-
munoassay with charcoal separation (21).
Statistical analysis
Results were expressed as mean and standard error of the mean
(X±SEM). For comparisons between two groups the paired or the
unpaired Student's t test (two tailed) were used as appropriate. For
multiple comparisons the one-way ANOVA was used. A P value of
< 0.05 was considered significant.
Results
Metabolic evolution after transplantation (Table I). All ani-
mals were comparable in age and body weight when injected
with streptozocin or citrate buffer at the start of the experi-
ments (data not shown). At the time ofthe transplantation the
six groups of streptozocin diabetic animals had similar blood
glucose values and body weight, and the same was true for the
two groups of nondiabetic animals. Initially, the diabetic ani-
mals that were not transplanted had blood glucose values and
body weights not different than those of the streptozocin ani-
mals that were transplanted. This nontransplanted group had
continuous clinical deterioration with persistent severe hyper-
glycemia and weight loss, and after 30 d of follow-up 45% of
these mice had died. In contrast, all transplanted animals
showed clinical improvement. The recipients of300 islets were
restored to normoglycemia after transplantation. By day 10
their mean blood glucose value was in the normal range, al-
though when compared with initially normoglycemic recipi-
ents it was still significantly elevated. By day 18 or 30 there
were no differences between the blood glucose values of ini-
tially diabetic and normoglycemic recipients of 300 islets.
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Table I. Characteristics ofExperimental Groups
Day transplant Day graft removal
Islets Days of Body Body
Group STZ* number transplant Glucose weight Glucose weight
mM/liter g mM/liter g
1 (n = 6) + 300 10 23.5±0.5* 23.4±1.1t 8.8±0.4§ 25.1±0.8
2 (n = 4) + 300 18 24.8±0.9* 23.0±1.2t 7.5±0.4 25.5±0.8
3 (n = 5) + 300 30 24.0±1.0* 23.4±1.0t 8.1±0.4 26.6±0.8
4 (n = 6) + 150 10 25.4±0.5* 21.9±0.4t 22.5±1.2 24.0±0.5
S (n = 6) + 150 18 23.8±0.6t 20.9±0.5$ 19.3±3.2 23.7±0.4
6 (n = 6) + 150 30 24.8±0.6$ 22.1±0.5$ 21.6±2.4 25.5±0.4
7 (n = 11) - 300 10 7.0±0.2 26.9±0.4 7.5±0.2 26.4±0.5
8(n= 11) - 300 30 7.4±0.2 26.9±0.4$ 7.1±0.1 29.4±0.9
9 (n = 9)11 + Nontransplanted 23.6±0.8 22.2±0.5 25.8±1.0 20.7±0.7
* STZ, streptozocin-induced diabetes. * P < 0.001 compared to day of graft removal. § P = 0.01 compared to group 7. 11 Group 9, nontrans-
planted streptozocin diabetic mice; in this group day transplant columns show blood glucose values and body weights 7 d after streptozocin
injection, and day graft removal columns show the values 30 d later. Values are mean±SEM.
When only 150 islets were transplanted all recipients but
one remained severely hyperglycemic. Even so, at the time of
graft removal blood glucose values were lower than at trans-
plantation and the body weights had increased.
The normoglycemic recipients of 300 islets showed no sig-
nificant change in blood glucose values after transplantation.
Their body weight was not increased by day 10, possibly due to
some loss associated with the surgical procedure, but thereafter
their weight gain was similar to normal animals.
Beta cell replication (Fig. 2). The diabetic mice in which
normoglycemia was restored with transplantation of 300 islets
(groups 1-3) had a beta cell replication similar to that of beta
cells in the normal pancreas. However, when the 10-d group
(group 1) was analyzed independently of the groups at 18 and
30 d (groups 2 and 3) its graft beta cell replication was signifi-
cantly higher than in normal pancreas (1.03±0.19% vs
0.49±0.06%, P < 0.05). As already described the blood glucose
of this group was slightly elevated. When hyperglycemia per-
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Figure 2. Beta cell replication in normal pancreas and in transplanted
islets. Replication is expressed as percentage of BrdU positive beta
cells. (STZ 300) Streptozocin diabetic mice transplanted with 300
islets. (STZ 150) Streptozocin diabetic mice transplanted with 150
islets (Tx normal) Normal mice transplanted with 300 islets. Num-
bers on the x axis correspond to transplanted groups shown in Table
I. Values are mean±SEM. *P < 0.05 between group 4 and all other
groups with the exception of group 1; *P < 0.05 between group 1
and normal pancreas.
sisted after transplantation (groups 4-6), beta cell replication
was increased. When groups were analyzed individually, only
group 4 (studied 10 d after transplantation) had a beta cell
replication significantly increased compared to normal pancre-
atic beta cells or to the transplanted islets under strict normogly-
cemic conditions (group 4: 1.39±0.11%, P < 0.05 vs groups 2,
3,7, and 8). After 18 d (group 5: 0.68±0.06%) and 30 d (group
6: 0.72±0.11 %) of hyperglycemia, transplanted islets no longer
maintained the increased beta cell replication found at day 10
(P < 0.01 vs group 4). Islets transplanted into normoglycemic
recipients had a beta cell replication similar to that of pancre-
atic islets of normal animals, both at day 10 (group 7:
0.71±0.11%) and at day 30 (group 8: 0.56±0.11%). The pan-
creatic beta cell replication of these nondiabetic transplanted
mice was also comparable after 10 d (group 7: 0.48±0.11%)
and 30 d (group 8: 0.57±0.07%).
Beta cell mass. The beta cell mass measured in groups of
150 and 300 isolated islets was 0.46±0.06 mg and 0.89±0.09
mg, respectively. The beta cell mass calculated from the mea-
surements of individual islet size was 0.51±0.6 mg and
1.02±0.10 mg, respectively, confirming the accuracy ofthe val-
ues based on the weight of the samples. Therefore, the values
obtained from the groups of isolated islets were used for com-
parison with the beta tell mass in the grafts. When 300 islets
were transplanted into streptozocin diabetic recipients and nor-
moglycemia was restored, the beta cell mass recovered from the
grafts after 10 d (group 1: 0.91±0.33 mg) or 30 d (group 3:
0.64±0.09 mg) was similar to the beta cell mass originally
transplanted (Fig. 3). On the other hand, when an insufficient
number of islets was transplanted, beta cell mass was reduced
by day 10 (group 4: 0.31±0.07 mg) with a further reduction
being found after 30 d (group 6: 0.17±0.03 mg) of hyperglyce-
mia (P < 0.001).
The beta cell mass transplanted into normal recipients was
significantly reduced at day 10 (group 7: 0.17±0.03 mg) and at
day 30 (group 8: 0.40±0.12 mg) (P < 0.001), although it
tended to recover partially at day 30 (P = 0.097 vs day 10) (Fig.
4 A). The beta cell mass of the endogenous pancreas was com-
parable to that of normal nontransplanted mice matched for
body weight (Fig. 5 A).
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Figure 3. Beta cell mass after transplantation into streptozocin dia-
betic mice. (STZ 300) Beta cell mass of 300 isolated islets and of
grafts of 300 islets. (STZ 150) Beta cell mass of 150 isolated islets and
of grafts of 150 islets. Numbers on the x axis correspond to trans-
planted groups shown in Table I. Values are mean±SEM. *P < 0.001
between 150 isolated islets, graft at day 10 (group 4), and graft at
day 30 (group 6).
Beta cell area (Fig. 6). The individual area of beta cells in
isolated islets was 271±14 AMm2. This value was higher than
what had been previously described for normal beta cells (22-
24), but as mentioned above, we expected an overestimation of
cell area with our method. However, since all samples were
processed and measured exactly in the same way, differences
A
*
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E GRAFT DAY 1O
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a GRAFT DAY 1O
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7 8
Figure 4. Graft beta cell mass and insulin content after transplanta-
tion into normal mice. Numbers on the x axis correspond to trans-
planted groups shown in Table I. Values are mean±SEM. (A) Beta
cell mass of 300 isolated islets and of grafts of 300 islets. *P < 0.001
between 300 islets after isolation, graft at day 10 (group 7), and graft
at day 30 (group 8). (B) Insulin content of 300 isolated islets and of
grafts of 300 islets. *P < 0.001 between 300 islets after isolation, graft
at day 10 (group 7), and graft at day 30 (group 8). tP < 0.01 between
day 10 and day 30 grafts.
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Figure 5. Pancreatic beta cell mass and insulin content of normal
nontransplanted mice and of nondiabetic transplanted mice. Num-
bers on the x axis correspond to transplanted groups shown in Table
I. Normal and transplanted groups were matched for body weight.
Values are mean±SEM. (A) Pancreatic beta cell mass of normal
nontransplanted mice and of mice after transplantation of 300 islets.
(B) Pancreatic insulin content of normal nontransplanted mice and
of mice after transplantation of 300 islets.
between groups reflected real changes in beta cell size. Beta
cells transplanted into diabetic recipients in which normoglyce-
mia was restored showed an increased area at day 30 -after
transplantation (group 3: 305±13 ,gm2) when compared to any
other transplanted group (P < 0.01). In contrast, islets trans-
planted into normal animals showed a significant reduction in
the area of beta cells 10 d after transplantation (group 7:
217±15 ,um2) compared to the beta cell area on the day of
transplantation (P < 0.05).
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Figure 6. Area of individual beta cells from isolated and transplanted
islets. (STZ 300) Streptozocin diabetic mice transplanted with 300
islets. (STZ 150) Streptozocin diabetic mice transplanted with 150
islets. (Tx normal) Normal mice transplanted with 300 islets. Num-
bers on the x axis correspond to transplanted groups shown in Table
I. Values are mean±SEM. *P < 0.01 between group 3 and all other
transplanted groups. tP < 0.05 between group 7 and isolated islets.
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Insulin content. The insulin content of grafts and endoge-
nous pancreas from normal mice transplanted with 300 islets
(groups 7 and 8) reflected the beta cell mass measurements.
These values were compared with the insulin content of 300
freshly isolated islets ( 16.2±2.0 jig) and of pancreas of normal
nontransplanted animals matched for body weight. There was
a significant reduction in the insulin content ofthe grafts at day
10 (group 7: 1.10±0.35 Mg) and at day 30 (group 8: 2.65±0.19
Mug) (P < 0.001) compared with 300 isolated islets, the 30-d
value being significantly higher than that at 10 d (P < 0.01)
(Fig. 4 B). No differences were found between the insulin con-
tent of the pancreas of transplanted and of control animals
matched for body weight (Fig. 5 B).
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We have studied the replicative capacity of transplanted beta
cells and the evolution of beta cell mass over the first month
after transplantation in models that reproduce three different
situations in islet transplantation: (a) transplantation of the
minimum amount ofbeta cell mass necessary to restore normo-
glycemia; (b) transplantation of a beta cell mass insufficient to
restore normoglycemia; (c) transplantation ofan excess ofbeta
cells. When a sufficient beta cell mass was transplanted, replica-
tion of beta cells was normal and the graft beta cell mass re-
mained unchanged. In contrast, ifan insufficient beta cell mass
was transplanted, a limitation in beta cell replication was found
and the graft beta cell mass declined progressively. Finally,
when an excessive beta cell mass was transplanted, the graft
beta cell mass diminished despite a normal replication.
When normoglycemia was restored by transplantation, the
replication of transplanted beta cells was similar to that ofpan-
creatic beta cells of normal animals. Beta cell replication was
determined by BrdU incorporation in cells in the S phase ofthe
cell cycle; this incorporation has been validated as an indicator
of proliferation in vivo ( 19) and represents a safer and more
rapid alternative to classic autoradiography with [3H ]-
thymidine. By double staining for BrdU and endocrine non-
beta cells we specifically assessed the replication of beta cells
instead of the total islet cell replication analyzed in previous
studies (25-30). Since the G2 phase and M phase of beta cells
have been estimated to be 5.5 h and 0.5 h, respectively (31 ),
the 6-h labeling period allowed BrdU incorporation into the
DNA without division of labeled cells. Indeed, we identified
occasional mitotic figures, but we were unable to find doublets
of BrdU-positive beta cells that would suggest the presence of
labeled daughter cells. The beta cell replication rate in these
normoglycemic animals agrees with our previous in vivo stud-
ies with young rats, in which - 0.5% of B cells had mitotic
figures 4 h after treatment with colchicine (32). Our incorpora-
tion of BrdU after a 6-h exposure would correspond to a cell
birth rate of 2-3% per 24 h, similar to other studies in adult
rodents (31-33). Beta cell replication was, however, increased
at day 10 after transplantation. At this time point the mean
blood glucose was still modestly, but significantly, elevated.
Since glucose is a known stimulus for beta cell replication, that
elevation was probably an important contributor to the in-
creased beta cell replication.
When islet transplantation was sufficient to restore normo-
glycemia, the beta cell mass of the graft on days 10 and 30 was
similar to the originally transplanted beta cell mass, and on day
30 the grafted beta cells had an increased size compared to all
other transplanted groups. Pancreatic islets are a highly vascu-
larized tissue and in the first days after transplantation they are
probably hypoxic. Islets in culture develop central necrotic
cores suggesting cell death due to anoxia, and the fraction ofthe
islet core that becomes necrotic correlates with the islet size
(34). Therefore, although we carefully selected the islets with a
diameter below 250 Mm for transplantation, we still expected
some degree of beta cell death due to hypoxia during the first
days. The transplantation procedure probably is associated
with some additional beta cell loss. Therefore the similarity
between transplanted and recovered beta cell mass by day 10 in
the successful transplantation model suggests that beta cell rep-
lication was able to compensate for any beta cell loss. By day 30
the increase in beta cell size also played a role in preserving the
total beta cell mass. The hypertrophy of these cells may reflect
the increased metabolic demand placed upon them to main-
tain normoglycemia in the recipient (24, 35, 36).
When an insufficient islet tissue was transplanted, an initial
increase in replication was found after 10 d of hyperglycemia.
The two- to threefold stimulation ofbeta cell growth was proba-
bly driven by hyperglycemia and is similar to that reported in
the presence of high glucose levels in both in vivo and in vitro
conditions (31, 37). However, after 18 and 30 d ofsevere hyper-
glycemia, this increased replication was not maintained, indi-
cating a limitation for growth capacity of transplanted beta
cells. The mechanisms underlying this limitation are un-
known. It cannot be caused by impaired -access of BrdU to
transplanted islets, since by 10 d after syngeneic transplanta-
tion the glomerular-like microvascular network of islets is re-
stored (38), and transplanted islets seem to be fully vascular-
ized by day 14 (39, 40). The presence of hyperglycemia could
diminish the blood flow in transplanted islets (41 ); however,
since hyperglycemic animals had the most BrdU labeling, this
effect is unlikely. Furthermore, the even distribution of BrdU-
positive cells throughout the graft suggests that BrdU was acces-
sible to all transplanted tissue. Although a growth limitation
due to the heterotopical location of the islets can not be ruled
out, in rodents the kidney capsule offers better growth condi-
tions than other common transplantation sites such as liver or
spleen (27). In addition, syngeneic islets transplanted under
the kidney capsule have a better long-term function than islets
transplanted into the portal vein (42). Growth after transplan-
tation has been shown to depend on the genetic background of
the recipient but no limitations have been previously described
for C57B1/6 mice (29, 43). Therefore, with hyperglycemia a
limitation for beta cell growth is revealed after an initially in-
creased replication.
There was a continuous decline in beta cell mass of the
grafts in chronically hyperglycemic animals in spite ofbeta cell
replication being increased by day 10. Our results suggest that
an increased beta cell destruction was occurring that overcame
the beta cell replicative capacity. The apparent discrepancy be-
tween beta cell replication and beta cell mass illustrates the
need to measure both factors to understand the determinants
ofbeta cell mass in islet transplantation. After 30 d the beta cell
mass was significantly lower and, despite the persistent hyper-
glycemia, the replication was no longer increased. Since no
changes in beta cell size were found in these groups, and since
the beta cell replication was comparable to that of the control
animals, a significant portion of the fall in beta cell mass must
be due to increased cell death. Previous studies have reported
that a critical beta cell mass must be transplanted to achieve
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normoglycemia ( 13, 14). In the light of our results that obser-
vation can be better understood: when hyperglycemia persists
after the transplantation of an insufficient beta cell mass, both
limited beta cell replication and accelerated beta cell death are
found, leading to a progressive reduction in beta cell mass and
failure of the transplant. In contrast, when sufficient beta cell
mass is transplanted, a balance among beta cell replication,
beta cell hypertrophy, and beta cell death is obtained, and, at
least during the first month, beta cell mass is kept reasonably
constant. Although no conclusive benefit has been shown, in-
sulin is a standard treatment in the first days after islet trans-
plantation in humans (3-5). Insulin treatment may protect
islets from some deleterious effects of hyperglycemia, reducing
beta cell loss.
When islets were transplanted into normoglycemic recipi-
ents, no changes were found in the replicative rate of either
transplanted and endogenous pancreatic beta cells. This find-
ing is in agreement with the normal beta cell replicative rate
found in the streptozocin diabetic groups when normoglyce-
mia was completely restored after transplantation (see above).
Therefore, our results consistently show a normal beta cell repli-
cation in transplanted islets of normoglycemic animals during
the first month.
In normal recipients the transplanted beta cell mass was
dramatically diminished at days 10 and 30, despite normal
replication of beta cells. This reduction was confirmed by a
similar decrease in the insulin content of the graft; in fact, the
reduction in insulin content was even more severe. An alter-
ation in storage of insulin in transplanted islets, or differences
in the efficiency of the insulin extraction from pure isolated
islets versus grafted islets could account for the severe reduc-
tion in insulin content. Immediately after transplantation these
normal recipients had an excess of beta cells, with the trans-
planted islets in addition to their endogenous pancreatic islets,
that theoretically could put them at risk for hypoglycemia.
Thus, a reduction in beta cell mass could be a protective re-
sponse against hypoglycemia. Although some reduction in the
beta cell mass of the pancreas might have been expected, we
were unable to find any significant changes in pancreatic beta
cell mass or insulin content. Perhaps the number of trans-
planted islets was not sufficient to modify the endogenous beta
cell tissue, particularly after the dramatic reduction in trans-
planted beta cell mass that occurred. The atrophy of the trans-
planted beta cells 10 d after transplantation shows that the
mechanisms underlying the reduction in beta cell mass are dif-
ferent from those causing the loss ofbeta cell mass in the chron-
ically hyperglycemic animals. The situation could be similar to
the atrophy of endogenous beta cells found in the presence of
an insulinoma (44). However, cell atrophy alone could not
account for the reduction in beta cell mass, and as there was no
apparent fall in replication, increased beta cell death was also
possibly occurring. During chronic hyperglycemia beta cell
function is abnormal (45) and reduced beta cell mass would
result from beta cell injury and death (46), while in a situation
of normoglycemia with excessive beta cell mass the reduction
would be secondary to beta cell atrophy and to cell death. Atro-
phied cells could act as a functional reserve for a situation of
higher demand, providing an extra source ofnew beta cells that
may be of critical importance in islet transplantation where, in
the absence of pancreatic ducts, the only source of new beta
cells is replication of the preexisting ones (47). We speculate
that the transplantation ofan excess ofbeta cells could provide
increased functional reserve and regenerative capacity that
could lead to longer lasting normoglycemia and, thus, be of
practical value;
In summary, when normoglycemia was maintained after
transplantation, the replication ofgrafted beta cells was similar
to that ofendogenous pancreatic beta cells; while in a hypergly-
cemic environment, the replication of transplanted beta cells
was initially increased but eventually became limited. Further-
more, the mass of transplanted beta cells was progressively re-
duced during hyperglycemia without changes in beta cell size
suggesting increased beta cell death. In contrast, when a suffi-
cient number of islets was transplanted, beta cell mass re-
mained constant after transplantation. When an excessive
number of islets were transplanted into normoglycemic recipi-
ents, beta cell sire and total beta cell mass were reduced, sug-
gesting that beta cell mass was downregulated to protect from
hypoglycemia.
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